Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

Published:2020-12-14 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ferrara Roberto¹,Imbimbo Martina²,Malouf Reem³,Paget-Bailly Sophie⁴⁵,Calais François⁶,Marchal Corynne⁷,Westeel Virginie⁴⁸⁹

Affiliation:

1. Thoracic Oncology Unit; Fondazione IRCSS Istituto Nazionale dei Tumori; Milano Italy

2. Department of Oncology; Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne; Lausanne Switzerland

3. National Perinatal Epidemiology Unit (NPEU); University of Oxford; Oxford UK

4. Methodological and Quality of Life in Oncology Unit; University Hospital of Besançon; Besançon France

5. Université de Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France; Besançon France

6. Bibliothèque universitaire de Santé; Université de Franche-Comté; Besançon France

7. Université de Franche-Comté; Besançon France

8. Department of Thoracic Oncology; University Hospital of Besançon; Besançon France

9. Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique; Besançon France

Publisher

Wiley

Subject

Pharmacology (medical)

Reference101 articles.

1. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer;Carbone;New England Journal of Medicine,2017

2. An open-label, randomized, phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (CheckMate 026) https://clinicaltrials.gov/ct2/show/NCT02041533

3. CheckMate 227: patient-reported outcomes of first-line nivolumab + ipilimumab in high tumor mutational burden advanced NSCLC;Brahmer;Journal of Thoracic Oncology,2018

4. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden;Hellmann;New England Journal of Medicine

5. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;New England Journal of Medicine,2019

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma;Biomedical Chromatography;2024-08-13

2. Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol;Cochrane Database of Systematic Reviews;2024-07-03

3. Pneumonitis Incidence in Patients With Metastatic Non-small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-Analysis;Cureus;2024-07-01

4. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis;Frontiers in Oncology;2024-06-21

5. Healthcare Resource Utilization and Associated Costs among Patients with Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy or Immunotherapy in Spain: A Single-Center, Real-World, Exploratory Study;Cancers;2024-05-30